Cyclosporine Ophthalmic

Introduction Overview

Generic Name

cyclosporine ophthalmic

Brand Name

Restasis

Dosage Form

ophthalmic emulsion (eye drops)

Drug Class

Miscellaneous ophthalmic agents

Pharmacokinetics

Absorption:
Cyclosporine ophthalmic emulsion is administered topically to the eye, where systemic absorption is minimal to negligible. The drug acts locally on ocular tissues to exert its immunomodulatory effects. Studies have demonstrated that systemic absorption after ocular administration is very low, thereby minimizing systemic exposure and associated systemic adverse effects. The topical delivery primarily targets ocular surface tissues including the conjunctiva and cornea.

Distribution:
Following topical administration, cyclosporine distributes mainly into the tear film, conjunctival cells, and corneal epithelium. Penetration beyond the conjunctiva into intraocular tissues is limited, which contributes to the localized action and safety profile. The drug’s lipophilic nature facilitates partitioning into ocular cell membranes, enhancing its efficacy in reducing local inflammation associated with dry eye disease. Due to minimal systemic absorption, distribution to systemic organs is not clinically significant.

Metabolism:
Cyclosporine is extensively metabolized by the cytochrome P450 (CYP) system, predominantly CYP3A enzymes, when administered systemically. However, with ophthalmic delivery, systemic metabolism of cyclosporine is minimal owing to negligible systemic absorption. Therefore, ocular biotransformation in the eye tissues is considered limited. The lack of extensive metabolism in the ocular environment helps maintain therapeutic concentrations at the site of action.

Elimination:
Systemic elimination of cyclosporine occurs mainly through biliary excretion of metabolites following hepatic metabolism when administered systemically. For the ophthalmic emulsion, local clearance mainly involves tear turnover, blinking, and nasolacrimal drainage. This results in the clearance of drug from the ocular surface, necessitating twice daily administration to maintain therapeutic levels. The elimination half-life in ocular tissues is not well defined but the dosing interval is guided by clinical efficacy.

Overall, the topical ophthalmic formulation of cyclosporine in Restasis limits systemic exposure, focusing drug action on ocular surface inflammation with a favorable pharmacokinetic profile for chronic dry eye treatment.

Dosage Forms

Available Dosage Forms:
Restasis is formulated as a sterile ophthalmic emulsion designed for topical ocular administration. The marketed formulations include:
- Single-use preservative-free vials for one-time use
- Multidose bottles with a specially designed dispenser to maintain sterility
Typical concentration is 0.05% cyclosporine by weight.

Dosages for Adults and Adolescents:
The recommended dosing regimen is 1 drop in each eye twice daily, approximately 12 hours apart. This schedule maintains effective local drug concentrations to reduce ocular surface inflammation and increase tear production. The medication should be used consistently for several months (often 3 to 6 months) until clinical improvement is evident.

Specific Patient Populations:
Restasis is not approved for use in individuals under 16 years of age. For pregnant or nursing women, although limited data suggest likely safety, use should be based on physician assessment considering potential risks and benefits. Caution is advised in patients with known hypersensitivity to cyclosporine or any formulation components. Patients wearing contact lenses should remove lenses prior to administration and wait at least 15 minutes before reinsertion.

Clinical guidelines emphasize strict adherence to dosing instructions including not touching the dropper tip to any surface to maintain sterility, discarding single-use vials after one use, and proper storage at room temperature away from heat and moisture to preserve drug stability.

Mechanism Of Action

Restasis contains cyclosporine, a potent immunosuppressant that acts primarily by inhibiting T-cell activation and cytokine release. At the molecular level, cyclosporine binds to the cytosolic protein cyclophilin in T lymphocytes, forming a cyclosporine-cyclophilin complex which inhibits calcineurin, a calcium/calmodulin-dependent phosphatase. Calcineurin inhibition prevents dephosphorylation and nuclear translocation of nuclear factor of activated T-cells (NFAT), thereby blocking the transcription of interleukin-2 (IL-2) and other cytokines essential for T-cell activation and proliferation.

In the context of dry eye disease, inflammation of the lacrimal gland and ocular surface leads to decreased tear production and increased ocular surface damage. Cyclosporine’s immunomodulatory action suppresses the inflammatory cascade within conjunctival and lacrimal tissues, leading to reversal of immune-mediated damage. This results in increased tear production, improved tear film stability, and enhanced ocular surface integrity.

Biochemically, cyclosporine's lipophilic properties allow it to penetrate ocular tissues effectively, where it inhibits production and release of pro-inflammatory cytokines such as IL-2, IL-6, tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ). These actions suppress T-cell mediated chronic inflammation, a key factor in the pathogenesis of keratoconjunctivitis sicca (dry eye).

Comparatively, unlike corticosteroids which provide broad immunosuppression but carry risks of increased intraocular pressure and cataracts, cyclosporine specifically targets T-cell activation without these adverse effects and is suitable for long-term use. Clinical trials have demonstrated that cyclosporine ophthalmic emulsion effectively increases basal tear production and reduces symptoms, confirming the importance of its targeted immunosuppressive mechanism in managing chronic dry eye.

Pharmacological Actions

Topical immunosuppressive action by inhibiting T-lymphocyte activation through calcineurin pathway.
Reduction of ocular surface inflammation associated with dry eye disease.
Increases basal tear production in patients with decreased tear volume due to inflammation.
Suppresses production of pro-inflammatory cytokines such as IL-2, IL-6, TNF-α, and IFN-γ in ocular tissues.
Improves tear film stability and ocular surface health by reversing immune-mediated damage.
Exhibits minimal systemic absorption, focusing effects locally in the eye.
Allows for long-term management of chronic dry eye without typical corticosteroid side effects.
Maintains ocular surface integrity by reducing inflammation-induced epithelial cell apoptosis.
Based on lipophilic emulsion formulation, enhances penetration through corneal and conjunctival epithelium.
Does not affect aqueous humor dynamics, intraocular pressure, or lens transparency.
Compatible with concurrent artificial tear use when administered 15 minutes apart.
Demonstrated clinical efficacy in multiple randomized controlled trials for keratoconjunctivitis sicca.
Sterile formulation reduces risk of ocular infections when used as directed.

Therapeutic Or Clinical Uses

Treatment of chronic dry eye disease characterized by ocular inflammation and decreased tear production.
Management of keratoconjunctivitis sicca due to immune-mediated lacrimal gland dysfunction.
Increasing basal tear production in patients with inadequate tear volume caused by ocular surface inflammation.
Adjunct to artificial tears in improving symptoms of moderate to severe dry eye syndrome.
Reducing signs and symptoms of ocular surface inflammation such as redness, burning, and irritation.
Use in patients inadequately responsive to lubricating eye drops alone.
Off-label use in other inflammatory ocular surface disorders as determined by ophthalmologists.
Long-term management option without corticosteroid-related risks such as elevated intraocular pressure.
Improving patient quality of life by restoring normal tear film dynamics and ocular comfort.
Reduces risk of corneal damage associated with chronic dry eye.
Part of comprehensive dry eye disease treatment including lid hygiene and environment control.
Useful in patients with dry eye secondary to autoimmune conditions like Sjögren’s syndrome.
May aid in recovery of ocular surface after refractive surgery or other ocular procedures causing dry eye.

Side Or Adverse Effects

Mild burning or stinging sensation upon instillation into the eye.
Transient ocular redness or conjunctival hyperemia.
Itching or irritation of the eyes shortly after application.
Blurred vision observed immediately after administration, typically resolving quickly.
A feeling of foreign body sensation or grittiness in the eyes.
Occasional eye pain or discomfort reported rarely.
Eye swelling and crusting may indicate infection if persistent.
Severe ocular discomfort or signs of allergic reaction requiring medical attention.
Rare occurrence of hypersensitivity reactions including hives, facial swelling, or respiratory difficulty.
Potential risk of eye infection if the dropper tip is contaminated by contact with surfaces or eyes.
Not commonly associated with systemic adverse effects due to minimal systemic absorption.
Symptoms typically mild and transient, often improving with continued treatment.
Discontinuation recommended if severe ocular adverse effects or signs of infection develop.
Reports of headache and ocular dryness are uncommon and typically unrelated.
Patients should notify healthcare providers for worsening ocular symptoms.

Precautions

Do not touch the tip of the dropper to any surface including the eye or hands to avoid contamination.
Avoid using Restasis while wearing contact lenses; remove lenses prior to application and wait 15 minutes before reinsertion.
Use only as prescribed and do not use larger or more frequent doses than recommended.
Monitor for signs of ocular infection such as redness, swelling, discharge, or pain.
Single-use vials should be discarded immediately after use even if some solution remains.
Ensure hands are washed thoroughly before and after administration to maintain sterility.
Avoid using if the solution changes color or contains particulate matter.
Inform your doctor if you are pregnant, planning pregnancy, or breastfeeding before using Restasis.
Not approved for use in patients younger than 16 years of age.
Use cautiously in patients with known hypersensitivity to cyclosporine or any formulation excipients.
Store at room temperature away from heat and moisture; do not freeze the product.
Avoid concurrent use of other ophthalmic medications within 15 minutes of applying Restasis unless instructed.
Patients with history of ocular herpes simplex infection should consult their healthcare provider prior to use.
Discontinue use and seek medical advice if severe ocular symptoms or allergic reactions occur.
Inform all healthcare providers about all medications being used to evaluate potential interactions.

Warnings

Strictly avoid contamination of the dropper tip to prevent serious eye infections.
Do not use this medicine while wearing contact lenses; lenses may be reinserted 15 minutes after use.
If an allergic reaction occurs, such as hives, swelling of the face, lips, tongue or throat, seek emergency medical attention immediately.
Stop using Restasis and contact a healthcare professional if there is eye pain, swelling, redness, severe discomfort, or discharge indicating infection.
Persistent burning or stinging beyond initial dosing period warrants medical evaluation.
Not approved for pediatric use under 16 years of age due to insufficient safety data.
Avoid exposure to conditions that might compromise sterility, as contaminated solution can cause severe ocular damage.
Use during pregnancy and breastfeeding should be based on physician's assessment weighing benefits versus risks.
Overdose is not expected to be dangerous; however, accidental ingestion requires medical attention.
Patients should report any vision changes promptly to their healthcare provider.
Long-term effects of chronic use have not shown major safety concerns but require periodic evaluation.
Medication should only be used for the indication prescribed to ensure safety and efficacy.
Avoid storing the drops in extreme temperatures as this can reduce effectiveness.
Discontinue immediately if any evidence of ocular infection or hypersensitivity develops.
Patients should keep all other eye medications and artificial tears at least 15 minutes apart from Restasis dosing.

Contraindication

Known hypersensitivity or allergy to cyclosporine or any component of the ophthalmic emulsion.
Active eye infections such as conjunctivitis or blepharitis at the time of initiation of therapy.
Patients with severe ocular surface disease where topical administration may exacerbate symptoms.
Use in pediatric patients less than 16 years of age, as safety and efficacy have not been established.
Avoid use if the medication appears discolored, cloudy, or contains particulates indicating contamination.
Contraindicated if the patient has experienced previous severe adverse reactions to topical cyclosporine preparations.
Patients unable to maintain sterility of the medication or follow administration instructions should avoid use.
Use contraindicated in cases of hypersensitivity to other immunosuppressants, pending physician discretion.
Not recommended for use in eyes that have undergone recent surgery unless prescribed by the surgeon.
Patients with known risk factors for ocular infections should be evaluated carefully before use.

Drug Interactions

Minimal systemic absorption of ophthalmic cyclosporine reduces the risk of systemic drug interactions.
No significant interactions expected with oral, intravenous, or topical drugs administered concurrently.
Use with other ophthalmic medications is generally safe but space administration by at least 15 minutes.
Artificial tears can be used concomitantly, ensuring a 15-minute interval before or after Restasis application.
Potential interaction with other topical immunosuppressants or corticosteroids should be monitored clinically.
Concurrent use with contact lenses requires removal before application and reapplication after 15 minutes to avoid interference.
No known interaction with systemic cytochrome P450 modulators due to negligible systemic exposure.
Concurrent use with other agents affecting ocular surface should be guided by physician to manage additive effects.
Patients should inform healthcare providers of all medications, including over-the-counter products and herbal supplements.
No reports of interactions leading to altered intraocular pressure or vision changes.
Use with ocular preservatives or preservatives in other eye drops should be monitored for additive irritation.
Limited data on interactions with other immunomodulatory ophthalmic agents; caution advised.
No contraindicated drug combinations identified with topical ocular cyclosporine.
Patient monitoring advised when switching between cyclosporine ophthalmic preparations.
No documented interactions with systemic immunosuppressive therapies at ocular dosage levels.

Preparations Of The Drug

Restasis Ophthalmic Emulsion 0.05% cyclosporine, available in single-use preservative-free vials.
Restasis Multidose bottles with 0.05% cyclosporine formulated with a specialized dispensing system.
Generic cyclosporine ophthalmic emulsion 0.05% in single-dose units as an alternative to the branded product.
Cequa (cyclosporine ophthalmic solution) 0.09%, utilizing nanomicellar technology for enhanced delivery.
Vevye, a cyclosporine 0.1% ophthalmic solution indicated for dry eye treatment.
Other related ophthalmic cyclosporine products approved for topical immunosuppression.
Preservative-free formulations designed to reduce ocular surface irritation in sensitive patients.
Emulsion formulation contains ingredients to stabilize cyclosporine and facilitate ocular tissue penetration.
Packaging designed to maintain sterility and prevent contamination during repeated use.
Storage instructions recommend room temperature, protected from moisture and heat.
Single-use vial design to ensure accurate dosing and prevent cross-contamination.
Refrigeration is not required and may adversely affect the emulsion consistency.
Patient information leaflets included to guide proper administration and handling.
Formulations for ophthalmic use differ significantly from systemic cyclosporine preparations in concentration and delivery.
Ongoing development of newer ophthalmic cyclosporine formulations targeting improved efficacy and tolerability.